76,660 Shares in TScan Therapeutics, Inc. $TCRX Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new position in TScan Therapeutics, Inc. (NASDAQ:TCRX) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 76,660 shares of the company’s stock, valued at approximately $111,000.

Other institutional investors have also recently bought and sold shares of the company. BVF Inc. IL grew its position in shares of TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after purchasing an additional 1,900,000 shares in the last quarter. Checkpoint Capital L.P. boosted its stake in shares of TScan Therapeutics by 14.9% in the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after buying an additional 261,663 shares during the period. Nuveen LLC bought a new stake in shares of TScan Therapeutics in the first quarter valued at approximately $97,000. Letko Brosseau & Associates Inc. grew its position in TScan Therapeutics by 113.0% during the first quarter. Letko Brosseau & Associates Inc. now owns 77,100 shares of the company’s stock worth $106,000 after buying an additional 40,900 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in TScan Therapeutics during the 1st quarter worth $49,000. Institutional investors own 82.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Tuesday, August 12th. Needham & Company LLC reduced their target price on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. BTIG Research cut TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.20.

TScan Therapeutics Price Performance

Shares of TCRX stock opened at $1.09 on Monday. The business has a fifty day simple moving average of $1.91 and a 200 day simple moving average of $1.72. The company has a market cap of $61.86 million, a P/E ratio of -1.00 and a beta of 1.00. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18. TScan Therapeutics, Inc. has a twelve month low of $1.02 and a twelve month high of $6.04.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. On average, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.